APA (7th ed.) Citation

Jin, Y., Zhu, J., Sheng, A., Lin, Q., Zhao, M., He, X., . . . Fu, H. (2025). Telitacicept as a BAFF/APRIL dual inhibitor: Efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatric Nephrology, 40(8), 2561. https://doi.org/10.1007/s00467-025-06769-3

Chicago Style (17th ed.) Citation

Jin, Yanyan, Jianhong Zhu, Aiqin Sheng, Qian Lin, Manli Zhao, Xue He, Jianhua Mao, and Haidong Fu. "Telitacicept as a BAFF/APRIL Dual Inhibitor: Efficacy and Safety in Reducing Proteinuria for Refractory Childhood IgA Vasculitis Nephritis." Pediatric Nephrology 40, no. 8 (2025): 2561. https://doi.org/10.1007/s00467-025-06769-3.

MLA (9th ed.) Citation

Jin, Yanyan, et al. "Telitacicept as a BAFF/APRIL Dual Inhibitor: Efficacy and Safety in Reducing Proteinuria for Refractory Childhood IgA Vasculitis Nephritis." Pediatric Nephrology, vol. 40, no. 8, 2025, p. 2561, https://doi.org/10.1007/s00467-025-06769-3.